Skip to main content
Clinical Trials/JPRN-jRCT1091220187
JPRN-jRCT1091220187CompletedPhase 1

Efficacy and safety of ferulic acid and Angelica archangelica extrac in patients with mild cognitive impairment (MCI): Double blind placebo-controlled study - FAMCIS

Hokuriku National Hospital0 sites20 target enrollmentStarted: July 15, 2014Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 60age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • 1.MCI outpatients older than 60 years old at informed consent.
  • 2.Patients with MCI who fulfilled the MCI criteria (Reisberg(1991); MayoClinic,Petersen(1995)).
  • 3.MMSE score 20-26 points and CDR score 0.5 or 1.
  • 4.Patient could be distinguished from other dementia disorders.
  • 5.Patient can administrate the tablets and patient and patient's family can manage taking medicine.
  • 6.Written informed consent of patient and patient's family.

Exclusion Criteria

  • 1.Patients taken supplements which contain polyphenols within 1 month.
  • 2.Patients with severe heart disease, liver disease, kidney disease.
  • 3.Patients who has malignancy.
  • 4.Patients who has previous history of alcohol and/or drug abuse.
  • 5.Patients who has hypersensitivity to polyphenols.
  • 6.Patients who has drug and/or food allergy.
  • 7.Patients participating in other clinical trials.
  • 8.Patients newly administrated other dementia therapeutics within 30 days including Galantamine Hydromide (Reminyl, Takeda pharmaceutical company limited. Janssen pharmaceutica), Memantine Hydrochoride (Memary, DaiichiSankyo company limited), Rivastigmine (Exelon patch, Novartis/ Rivastach patch, Ono pharmaceutical company limited), Donepezil Hydrochloride (Aricept, Aricept D, Eisai). During this trial, addition and change of other dementia therapeutic drugs are not permitted in principle.
  • 9.The patients judged to inadequacy by the attending physician or principal investigator.

Investigators

Sponsor
Hokuriku National Hospital

Similar Trials